Today's News | Note: News feeds may no longer be available for the articles on this page.

Amgen shares jump on bone-cancer drug trial results 6:00 AM 7/8/2009
Los Angeles Times - CA,USA
Amgen said its experimental osteoporosis drug denosumab reduced and delayed serious bone complications among patients with advanced breast cancer. Denosumab proved superior to Novartis' Zometa in a late-stage study. ...

Abbott Wins Ruling Tossing AIDS-Drug Monopoly Claims 1:02 AM 7/8/2009
Bloomberg - USA
Abbott Laboratories wins a federal appeals court ruling which dismisses claims that it maintained a monopoly and overcharged for its HIV medicine Norvir. ...

Pain Therapeutics Down On Remoxy Application Delay 1:56 PM 7/7/2009
Wall Street Journal - USA
King Pharmaceuticals and partner Pain Therapeutics Inc expect to resubmit the application for abuse-resistant painkiller Remoxy to the US FDA in the middle of next year. ...

Trinity Biotech's blood-clot analyzer gets FDA nod 9:34 AM 7/7/2009
Reuters - USA
Medical device maker Trinity Biotech said US FDA approved its blood-clot analyzer Destiny Max. ...

Shire Seeks FDA OK To Provide Vela Amid Drug Shortage 5:16 AM 7/7/2009
Wall Street Journal - USA
Following the shortage of Genzyme's Cerezyme for Gaucher disease, Shire PLC filed a treatment protocol for Vela (velaglucerase alfa) at the request of the US FDA. ...

Lundbeck buys Danish biotech firm NeuronIcon 3:37 AM 7/7/2009
Reuters - USA
Danish pharmaceuticals group H. Lundbeck A/S will buy privately owned biotechnology firm NeuronIcon to gain technology to treat brain damage. ...

DOJ Shifts Policy on Generic Drug Patent Settlements 5:08 PM 7/6/2009
Wall Street Journal - USA
The US Department of Justice took a skeptical view on the legality of pharmaceutical patent settlements that delay the introduction of generic drugs. Patent settlements should be presumed unlawful when branded drug makers pay others to abandon challenges that could lead to early market entry of generics. ...

FDA approves new use for Lilly cancer drug Alimta 10:40 AM 7/6/2009
Forbes - NY,USA
Eli Lilly and Co said the US FDA approved a new use for its cancer treatment Alimta as a maintenance treatment for advanced cases of non-small cell lung cancer. ...

FDA tries to speed access to Protalix Gaucher drug 9:52 AM 7/6/2009
Reuters - USA
Protalix BioTherapeutics Inc has been approached by the US FDA to expand access to its experimental drug for Gaucher disease to help offset likely shortages of alternative drug Cerezyme made by Genzyme Corp. ...

EU approves Actelion's Tracleer for children 5:38 AM 7/6/2009
Reuters - USA
European regulators approved Actelion's Tracleer for the treatment of the heart and lung condition pulmonary arterial hypertension (PAH) in children. ...

Big push underway for generic biotech drugs 6:41 PM 7/3/2009
San Jose Mercury News - CA, USA
The Hatch-Waxman Act paved the path for generic versions of chemically synthesized drugs. Biologic drugs fell under different rules because of their complexity which remains a hurdle to copying. ...

Novo Nordisk Diabetes Drug Victoza Gets EU Approval 6:42 AM 7/3/2009
Wall Street Journal - USA
Novo Nordisk said the European Commission has given market authorization for its diabetes treatment Victoza (liraglutide) in the European Union member states. ...

Biogen Buys Rights to Acorda's MS Pill Outside US 2:25 PM 7/2/2009
Bloomberg - USA
Biogen Idec Inc will pay as much as $510 million for rights to market Acorda Therapeutics Inc’s experimental MS pill Fampridine SR outside the US. ...

Johnson & Johnson Buys Access to Alzheimer's Drug 8:39 AM 7/2/2009
New York Times - United States
Johnson & Johnson will acquire nearly all of the assets and rights of Elan related to its Alzheimer’s Immunotherapy Program through a new company. J&J will also invest $1 billion in Elan in exchange for American depositary receipts equivalent to 18.4 percent of Elan. ...

Europe biotechs see light at end of funding tunnel 7:39 AM 7/2/2009
Reuters - USA
Drug discovery firms have struggled to raise funds during the financial crisis. Industry insiders see some signs of confidence creeping back into the sector. ...

<- Day Earlier | Today's News